Clinical Trials Logo
  1. Home
  2. Malignant Ascites
  3. NCT04051112

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

Malignant Ascites Clinical Trial

Official title:
A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Ascites

Clinical Trial Summary

1. The safety and tolerability of single-dose of SCB-313 will be evaluated by intraperitoneal injection; 2. The safety and tolerability of repeated-dose of SCB-313 will be evaluated by intraperitoneal injection once a day for 3 days, and the maximum tolerated dose (MTD) of SCB-313 will be determined;

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04051112
Study type Interventional
Source Sichuan Clover Biopharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 1
Start date September 28, 2019
Completion date April 21, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06200376 - A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer Phase 1
Completed NCT00836654 - Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group Phase 2/Phase 3
Not yet recruiting NCT05501340 - PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Phase 1/Phase 2
Not yet recruiting NCT03550560 - EUS-Guided Drainage of Refractory Malignant Ascites
Recruiting NCT04501744 - A Study of M701 (EpCAM and CD3) in Malignant Ascites Phase 1
Terminated NCT00028782 - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer N/A
Recruiting NCT05477927 - Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases Phase 1
Active, not recruiting NCT06266091 - Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody Phase 2
Withdrawn NCT04076566 - Malignant Ascites Alfapump® Study
Enrolling by invitation NCT01854866 - Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion Phase 2
Recruiting NCT03230708 - Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites Phase 1/Phase 2
Completed NCT01327235 - Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Phase 2
Recruiting NCT06432296 - Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody Phase 3
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Terminated NCT02496286 - Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites Phase 1
Completed NCT01532427 - ALFApump System Post Marketing Surveillance Registry
Completed NCT00326885 - Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Phase 2
Recruiting NCT02530398 - A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites Phase 1
Withdrawn NCT00908219 - A Study of Bevacizumab to Prevent Malignant Ascites Phase 2
Recruiting NCT06016179 - Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Phase 1